Drug and Therapeutics Bulletin 1995;33:25-27; doi:10.1136/dtb.1995.33425
Copyright © 1995 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Magnesium, myocardial infarction, meta-analysis and megatrials

In 1992 we recommended that, barring contraindications, magnesium should be given to all patients with a suspected myocardial infarction.1 A meta-analysis of 7 randomised controlled trials (1300 patients in all) had suggested that prompt intravenous infusion of magnesium could reduce early mortality by half.2 Then the larger LIMIT-2 trial involving 2316 patients found that early mortality was reduced by about a quarter among those allocated magnesium.3 It was this trial that prompted our recommendations. Last month, however, the results of a very much larger trial, this time involving over 58 000 patients, suggested that magnesium was of no benefit.4 In this article we review the place of magnesium in the treatment of patients with myocardial infarction, using the review to illustrate the differences between meta-analysis and megatrials.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1995 BMJ Publishing Group Ltd.